Neurocrine Biosciences | NBIX - 资产



金融业
股票价格
USD
资产
USD 4.91B
现金及等价物
USD 266.5M
销售成本
USD 13.8M
流动资产
USD 2.44B
流动负债
USD 831.7M
债务
USD 406.2M
EBIT
USD 214.6M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 1.94
股本和储备
USD 3.41B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 15.47B
净收入
USD 197.9M
营业费用
USD 599.9M
营业利润
USD 214.6M
普通股股本
USD 100.6M
PE价格收益
28.09
税前利润
USD 246.8M
销售收入
USD 811M
销售和管理费用
USD 318.5M
股票
USD 64.5M
贸易债权人
USD 691.3M
应收帐款人
USD 768.1M


资产 更改 日
AbbVie USD 136.46B 2.5B 2026-03
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
ALKERMES USD 4.26B 1.77B 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Cytokinetics USD 1.27B 151.06M 2026-03
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Exelixis USD 2.59B 250.83M 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Pfizer USD 207.62B 542M 2026-03
Prothena USD 349.89M 23.09M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Repligen USD 2.93B 18.93M 2026-03
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Teva Pharmaceutical Industries USD 40.04B 708M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03
Xoma USD 263.15M 39.7M 2025-09